Gilead Sciences to Acquire Arcellx After Regulatory Approval
Gilead Sciences (GILD) has secured regulatory approvals for its acquisition of Arcellx, extending the tender offer for Arcellx shares. The deal is expected to strengthen Gilead's position in the biotech sector. Truist raised Gilead's price target to $155, citing increased deal activity and anticipation of management updates on product launches.
Topics: acquisition biotech pharmaceuticals regulatory approval stock price target